PBM
NASDAQ HealthcarePsyence Biomedical Ltd. - Ordinary Shares
Biotechnology
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
๐ Market Data
| Price | $6.62 |
|---|---|
| Volume | 133,141 |
| Beta | 1.730 |
| RSI (14-Day) | 90.4 Overbought |
| 200-Day MA | $10.32 |
| 50-Day MA | $3.88 |
| 52-Week High | $216.41 |
| 52-Week Low | $1.92 |
| Price / Book | 0.90 |
๐ฏ Investment Strategy Scores
PBM scores across each investment strategy. Higher is better for that strategy's goals.
๐ Learn More
Indicators on this page
Educational articles
Find PBM in your text
Paste any article, transcript, or post โ the tool will extract PBM and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.